About HS Pharmaceuticals

HS Pharmaceuticals, LLC is an early stage, privately-held and managed, nano-silicate based bio-pharmaceutical company focused on developing novel therapeutics for complex/infected wounds and oncology within Human Health and Animal Science.

Working with world class thought leaders and scientists skilled in the art, HS Pharma leads the field in silicate nanoparticle therapeutics, aiming to maximize global patient benefit along with shareholder value through the initial clinical development and out-licensing of its novel silicate-based nanoparticle technology.

HS Pharma’s business model is simple and based upon global connectivity: with our strong team of seasoned business executives, leading scientific advisors, and experienced drug development consultants serving in a cohesive yet virtual capacity, we develop and out-license innovative technologies to pharmaceutical companies having significant anti-infective/ wound repair and oncology market presence.

To increase the odds of success and bring our innovative technologies to market faster, we continue to engage in dialogue with prospective partners early in the drug development cycle and foresee an initial potential exit via out-licensing for an HS-7 based topical therapeutic focused on complex/infected wounds.